A small molecule inhibitor of Bcl-2 achieved high response rates in patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) and has been approved by the U.S. FDA (Genentech/AbbVie)49, validating apoptosis as a target pathway for cancer therapy. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.